论文部分内容阅读
目的探讨ERCC1(C118T)、XRCC1(G399A)的单核苷酸多态性(SNP)与非小细胞肺癌(NSCLC)对铂类为主化疗方案敏感性的关系。方法经病理学确诊的晚期NSCLC患者120例,采用铂类为主的两药联合化疗方案,2～3个周期后进行临床疗效评价。根据cDNA芯片原理制作目的基因芯片,利用双色荧光探针杂交进行ERCC1、XRCC1的多态性的基因分型,比较不同基因型与化疗敏感性的关系。结果 ERCC1(C118T)至少携带1个T等位基因型的患者化疗有效率为44.7%,显著高于C/C基因型的19.2%(P<0.05);携带XRCC1(G399A)G/G基因型者化疗有效率为43.8%,高于至少携带1个A等位基因的19.4%(P<0.05)。结论 ERCC1、XRCC1基因多态性与NSCLC患者对铂类药物化疗的敏感性相关。
Objective To investigate the relationship between the single nucleotide polymorphisms (SNPs) of ERCC1 (C118T), XRCC1 (G399A) and the sensitivity of non-small cell lung cancer (NSCLC) to platinum-based chemotherapies. Methods A total of 120 patients with advanced NSCLC diagnosed by pathology were randomly divided into two groups: the platinum-based combination chemotherapy and two to three cycles of chemotherapy. According to the principle of cDNA microarray, the gene chip of interest was made. The genotypes of ERCC1 and XRCC1 were analyzed by two-color fluorescent probe hybridization. The relationship between different genotypes and chemosensitivity was compared. Results The effective rate of chemotherapy in patients with ERCC1 (C118T) carrying at least one T allele was 44.7%, significantly higher than that of C / C genotype (19.2%, P <0.05). The patients with XRCC1 (G399A) G / G genotype The rate of chemotherapy was 43.8%, which was higher than 19.4% (P <0.05) of carrying at least one A allele. Conclusion The polymorphisms of ERCC1 and XRCC1 are associated with the sensitivity of NSCLC patients to platinum chemotherapy.